| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
4
| Silber Christopher (Chief Medical Officer) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 330,000 options to buy
@ $6.16, valued at
$2M
|
|
| 08/07/2023 |
3
| Silber Christopher (Chief Medical Officer) has filed a Form 3 on Vigil Neuroscience, Inc. |
| 06/09/2023 |
4
| Bruhn Suzanne Louise (Director) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 13,928 options to buy
@ $10, valued at
$139.3k
|
|
| 06/09/2023 |
4
| Thistle Mary (Director) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 13,928 options to buy
@ $10, valued at
$139.3k
|
|
| 06/09/2023 |
4
| Koenig Gerhard (Director) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 13,928 options to buy
@ $10, valued at
$139.3k
|
|
| 06/09/2023 |
4
| Blanchard Cheryl R (Director) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 13,928 options to buy
@ $10, valued at
$139.3k
|
|
| 06/09/2023 |
4
| Vitorovic Stefan (Director) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 13,928 options to buy
@ $10, valued at
$139.3k
|
|
| 06/09/2023 |
4
| Booth Bruce (Director) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 13,928 options to buy
@ $10, valued at
$139.3k
|
|
| 06/09/2023 |
4
| Budd Haeberlein Samantha L. (Director) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 13,928 options to buy
@ $10, valued at
$139.3k
|
|
| 06/08/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
4
| Budd Haeberlein Samantha L. (Director) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 30,694 options to buy
@ $9.65, valued at
$296.2k
|
|
| 05/09/2023 |
3
| Budd Haeberlein Samantha L. (Director) has filed a Form 3 on Vigil Neuroscience, Inc. |
| 05/09/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/21/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/21/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/21/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/27/2023 |
4
| Gray David L. F. (Chief Science Officer) has filed a Form 4 on Vigil Neuroscience, Inc.|
Txns:
| Granted 267,000 options to buy
@ $12.09, valued at
$3.2M
|
|
| 02/27/2023 |
3
| Gray David L. F. (Chief Science Officer) has filed a Form 3 on Vigil Neuroscience, Inc. |
| 02/14/2023 |
SC 13G
| Hatteras Venture Partners VI, LP reports a 4.4% stake in Vigil Neuroscience, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
|